Nikhraj S Brar, MD
Physical Medicine and Rehabilitation · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Office
- 1
- Since medical school
- 16 years
- University of California, Irvine, California College of Medicine, 2010
Offices
1 location · University of California San Francisco · 1,780 clinicians in this group
Hospitals listed: Henry Mayo Newhall Hospital · Providence Holy Cross Medical Center · UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Brar’s office at (415) 476-4029 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A121052 · Current
Licensed to practise in California · since 2012 · expires 2027-10-31 · University of California, Irvine College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Physical Medicine and Rehabilitation - Pain Medicine
- American Board of Physical Medicine and Rehabilitation - Physical Medicine and Rehabilitation
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Henry Mayo Newhall HospitalValencia, CAAcute Care Hospital · Voluntary non-profit - Private · No emergency department · Birthing-friendlyPatients rate it 3 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Pressure ulcer rate: 1.42 (0.65 to 2.18) · 4,172 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.206, Oct 2024 – Sep 2025
- Providence Holy Cross Medical CenterMission Hills, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.404, Oct 2024 – Sep 2025
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Henry Mayo Newhall Hospital
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 3 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 1.42 (0.65 to 2.18) · 4,172 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.206 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.37 (0.37 to 2.37) · 885 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.22 (0.84 to 1.6) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 172.82 (119.12 to 226.52) · 39 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.7 · 122 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.6 · 128 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11 · 285 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.6 · 410 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 214 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 2,687 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,440 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 4,489 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.34 (1.07 to 5.61) · 837 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.32) · 193 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.23 (0.64 to 3.81) · 798 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.74 (0.67 to 18.81) · 197 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.72 (0.6 to 8.85) · 177 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.99 (0.5 to 3.48) · 179 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 6.2 · 66 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.405 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 2.021 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.067 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.091 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.1 · 254 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.7 · 586 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 52.4 · 118 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 21.4 · 333 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 27.4 · 443 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 628 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12 · 31 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.9 · 225 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.3 (10.8 to 19.1) · 246 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 302 cases | No different | Jan 2024 – Dec 2024 |
What patients said (607 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Providence Holy Cross Medical Center
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 7 the same, 0 worse of 8 measures. Readmissions: 1 better, 7 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.404 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.05 to 1.9) · 1,299 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.93 (0.62 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 168.53 (119.32 to 217.74) · 78 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 42 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.1 · 84 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.7 · 496 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.9 · 297 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 316 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 2,960 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0.01 to 0.42) · 5,542 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.06 to 0.45) · 5,701 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.08 (1.02 to 5.14) · 1,284 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.44 (0 to 3.05) · 343 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.92 (0.45 to 3.4) · 1,235 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.25 (4.38 to 18.11) · 383 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.75 (2.09 to 9.41) · 353 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.96 (0.48 to 3.44) · 313 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.29 (0 to 0.91) · 4,791 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 166 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.258 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.091 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.947 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.638 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.691 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.4 · 196 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.1 · 948 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -36.2 · 85 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 0.1 · 626 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 10.5 · 315 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17 · 548 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.3 to 8.1) · 30 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.4 (7.2 to 15) · 30 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.7 · 39 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.3 · 104 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.8 to 17.5) · 218 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.3 (0.9 to 1.7) · 119 cases | No different | Jan 2024 – Dec 2024 |
What patients said (439 patients answered, 15% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$60,285
Medicare paid this office $60,285 for 167 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 90 | $16,304 | $96 |
| Short return visit (20+ min) | 88 | $12,689 | $73 |
| New patient visit (45+ min) | 31 | $4,173 | $135 |
| New patient visit (30+ min) | 40 | $3,816 | $95 |
| Injection of substance into lower spine canal using imaging guidance | 38 | $3,588 | $83 |
See all 10 services
| Return visit (30+ min) | 90 | $16,304 | $96 |
| Short return visit (20+ min) | 88 | $12,689 | $73 |
| New patient visit (45+ min) | 31 | $4,173 | $135 |
| New patient visit (30+ min) | 40 | $3,816 | $95 |
| Injection of substance into lower spine canal using imaging guidance | 38 | $3,588 | $83 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 90 | $2,875 | $14 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 14 | $1,580 | $88 |
| Injection of trigger points, 3 or more muscles | 15 | $1,063 | $48 |
| Aspiration and/or injection of fluid from large joint | 12 | $1,061 | $59 |
| Fluoroscopic guidance for needle placement | 16 | $452 | $23 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Injection of substance into lower spine canal using imaging guidance | – | – | 25 | 24 | 21 | 43 |
| Aspiration and/or injection of fluid from large joint | – | – | – | 22 | 15 | 18 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | – | – | – | – | 14 | 18 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | – | – | 23 | – | – | – |
| Injection of trigger points, 3 or more muscles | – | – | – | – | – | 22 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | – | – | 21 | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
167 Original Medicare patients in 2024. Average age 72 · Under 65 17% · 85 and older 11% · Women 58% · Also on Medicaid 42% · Health risk score 1.53. At or below the middle of the specialty; the typical physical medicine and rehabilitation clinician is at 1.53.
Conditions among them: High blood pressure 75% · Diabetes 43% · Depression 32% · Coronary heart disease 30% · Chronic kidney disease 28% · COPD 18% · Cancer 17% · Heart failure 16% · Atrial fibrillation 10% · Dementia 8% · Stroke 7%.
The office billed $298,034, Medicare allowed $80,058 and paid $60,285; for 958 services of 40 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 167 | 958 | 72 | 1.53 | $298,034 | $60,285 |
| 2023 | 133 | 506 | 71 | 1.70 | $214,342 | $42,700 |
| 2022 | 121 | 454 | 72 | 1.75 | $165,070 | $38,834 |
| 2021 | 100 | 516 | 72 | 1.55 | $161,016 | $45,057 |
| 2020 | 67 | 387 | 72 | 2.02 | $111,618 | $29,497 |
| 2019 | 31 | 137 | 70 | 2.60 | $32,861 | $9,140 |
| 2018 | 222 | 2,107 | 67 | 1.44 | $167,969 | $30,969 |
| 2017 | 429 | 2,597 | 65 | 1.49 | $521,906 | $90,959 |
| 2016 | 446 | 1,788 | 63 | 1.60 | $519,309 | $120,706 |
| 2015 | 76 | 144 | 61 | 1.58 | $37,302 | $10,718 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Return visit (30+ min) | 76 | $14,976 | $103 |
| Short return visit (20+ min) | 55 | $7,652 | $73 |
| New patient visit (45+ min) | 44 | $5,959 | $135 |
| New patient visit (30+ min) | 25 | $2,210 | $88 |
| Injection of substance into lower spine canal using imaging guidance | 19 | $1,699 | $81 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 11 | $1,252 | $89 |
| Aspiration and/or injection of fluid from large joint | 12 | $599 | $40 |
| Fluoroscopic guidance for needle placement | 13 | $372 | $22 |
2022: 6 services
| Return visit (30+ min) | 55 | $9,537 | $105 |
| Short return visit (20+ min) | 67 | $9,074 | $74 |
| New patient visit (45+ min) | 26 | $3,400 | $131 |
| New patient visit (30+ min) | 32 | $2,923 | $91 |
| Injection of substance into lower spine canal using imaging guidance | 19 | $1,988 | $83 |
| Aspiration and/or injection of fluid from large joint | 16 | $1,320 | $60 |
2021: 8 services
| Short return visit (20+ min) | 67 | $11,731 | $79 |
| Return visit (30+ min) | 55 | $11,047 | $113 |
| New patient visit (30+ min) | 38 | $3,511 | $92 |
| New patient visit (45+ min) | 24 | $3,390 | $141 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 17 | $2,643 | $115 |
| Injection of substance into lower spine canal using imaging guidance | 21 | $2,091 | $84 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 15 | $1,355 | $65 |
| Injection of trigger points, 1-2 muscles | 12 | $836 | $49 |
2020: 4 services
| Return visit (30+ min) | 35 | $5,371 | $93 |
| Short return visit (20+ min) | 35 | $3,971 | $65 |
| New patient visit (45+ min) | 21 | $2,706 | $129 |
| New patient visit (30+ min) | 29 | $2,645 | $91 |
2019: 3 services
| New patient visit (45+ min) | 16 | $2,264 | $141 |
| Short return visit (20+ min) | 14 | $1,562 | $65 |
| New patient visit (30+ min) | 13 | $1,228 | $94 |
2018: 9 services
| Short return visit (20+ min) | 107 | $5,794 | $43 |
| Short return visit | 112 | $4,208 | $30 |
| New patient visit (30+ min) | 52 | $3,169 | $61 |
| Injection of substance into lower spine canal using imaging guidance | 28 | $1,703 | $55 |
| Return visit (30+ min) | 13 | $1,104 | $85 |
| Aspiration and/or injection of fluid from large joint | 16 | $827 | $52 |
| Injection of trigger points, 1-2 muscles | 17 | $652 | $38 |
| Injection, methylprednisolone acetate, 40 mg | 13 | $89 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 13 | $5 | None |
2017: 18 services
| Short return visit (20+ min) | 235 | $20,332 | $53 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 39 | $9,738 | $187 |
| Injection of substance into lower spine canal using imaging guidance | 83 | $8,878 | $75 |
| Short return visit | 169 | $7,549 | $33 |
| New patient visit (30+ min) | 83 | $6,769 | $82 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 33 | $4,367 | $89 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 39 | $2,569 | $48 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 32 | $2,267 | $47 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 16 | $1,909 | $95 |
| Injection of substance into middle or upper spine canal using imaging guidance | 18 | $1,619 | $81 |
| Injection of upper or middle spine facet joint using imaging guidance, single level | 11 | $1,572 | $98 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 16 | $1,520 | $80 |
| Aspiration and/or injection of fluid from large joint | 21 | $1,366 | $49 |
| Aspiration and/or injection of fluid from large joint | 21 | $1,111 | $40 |
| Injection of trigger points, 1-2 muscles | 16 | $663 | $37 |
| Fluoroscopic guidance for needle placement | 20 | $573 | $22 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 15 | $76 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 17 | $9 | None |
2016: 25 services
| Short return visit (20+ min) | 252 | $29,937 | $57 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 80 | $13,174 | $91 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 37 | $8,558 | $214 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 79 | $7,187 | $51 |
| Injections of substances into lower or sacral spine | 76 | $6,912 | $73 |
| New patient visit (30+ min) | 91 | $6,787 | $75 |
| Return visit (30+ min) | 65 | $5,992 | $81 |
| Injection of upper or middle spine facet joint using imaging guidance, single level | 25 | $4,520 | $98 |
| Injections of substances into upper or middle spine | 40 | $4,176 | $89 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 36 | $4,010 | $98 |
| Destruction of upper or middle spinal facet joint nerves using imaging guidance, single facet joint | 15 | $4,000 | $190 |
| Short return visit | 76 | $3,172 | $34 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 35 | $2,311 | $56 |
| New patient visit (45+ min) | 17 | $2,158 | $127 |
| Injection of upper or middle spine facet joint using imaging guidance, second level | 20 | $2,070 | $54 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 22 | $1,995 | $83 |
| Destruction of peripheral nerve or branch | 15 | $1,990 | $59 |
| Aspiration and/or injection of fluid from large joint | 28 | $1,721 | $49 |
| Aspiration and/or injection of fluid from large joint | 27 | $1,217 | $39 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 16 | $1,191 | $30 |
| Destruction of upper or middle spinal facet joint nerves using imaging guidance, each additional facet joint | 13 | $994 | $58 |
| Fluoroscopic guidance for needle placement | 34 | $897 | $22 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 14 | $711 | $44 |
| Injection of trigger points, 1-2 muscles | 13 | $642 | $46 |
| Injection of trigger points, 1-2 muscles | 16 | $531 | $30 |
2015: 3 services
| Return visit (30+ min) | 24 | $2,400 | $86 |
| Short return visit (20+ min) | 30 | $2,056 | $59 |
| New patient visit (30+ min) | 13 | $1,068 | $82 |
Medicaid work
$741 in 2024
Medicaid paid $741 for 26 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 26 | $741 |
| 2024 | 26 | 1 | 14 | $741 |
| 2023 | 78 | 1 | 21 | $2,437 |
| 2022 | 56 | 2 | 15 | $898 |
| 2021 | 27 | 2 | 15 | $730 |
| 2018 | 785 | 7 | 91 | $54,756 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 78 | $2,437 |
2022
| Short return visit (20+ min) | 42 | $561 |
| Return visit (30+ min) | 14 | $338 |
2021
| Return visit (30+ min) | 15 | $528 |
| Short return visit (20+ min) | 12 | $202 |
2018
| Clinic visit/encounter, all-inclusive | 406 | $35,977 |
| Service | 69 | $10,315 |
| Short return visit (20+ min) | 178 | $3,782 |
| NJX INTERLAMINAR LMBR/SAC | 13 | $2,220 |
| New patient visit (30+ min) | 25 | $1,373 |
| Short return visit | 65 | $1,086 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 29 | $4 |
Drugs they prescribed that Part D paid
$4,645
Pharmacies billed $4,645 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 283) in 2024. At or below the middle of the specialty; the typical physical medicine and rehabilitation clinician is at 12%.
281 generic and fewer than 11 brand-name prescriptions · $4,645 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Duloxetine | 31 | $1,362 | $44 |
| Methocarbamol | 50 | $691 | $14 |
| Pregabalin | 37 | $474 | $13 |
| Gabapentin | 37 | $375 | $10 |
| Diclofenac | 17 | $264 | $16 |
See all 9 drugs
| Duloxetine | 31 | $1,362 | $44 |
| Methocarbamol | 50 | $691 | $14 |
| Pregabalin | 37 | $474 | $13 |
| Gabapentin | 37 | $375 | $10 |
| Diclofenac | 17 | $264 | $16 |
| Baclofen | 11 | $180 | $16 |
| Ibuprofen | 17 | $113 | $7 |
| Meloxicam | 25 | $84 | $3 |
| Tizanidine | 12 | $47 | $4 |
Year by year
| 2024 | 283 | 65 | 0% (0) | None | $4,645 |
| 2023 | 251 | 69 | None | 0% | $4,700 |
| 2022 | 125 | 44 | 0% (0) | None | $4,673 |
| 2021 | 96 | 36 | None | None | $3,694 |
| 2020 | 116 | 38 | 0% (0) | None | $2,687 |
| 2019 | 19 | None | 0% (0) | None | $954 |
| 2018 | 69 | 20 | None | None | $3,811 |
| 2017 | 573 | 150 | 16% (92) | 5% | $22,311 |
| 2016 | 2,124 | 269 | 43% (919) | 9% | $135,320 |
| 2015 | 429 | 122 | 50% (216) | 15% | $40,880 |
| 2014 | 23 | 12 | None | 57% | $5,469 |
| 2013 | 60 | 17 | None | None | $2,810 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Pregabalin | 34 | $1,306 | $38 |
| Methocarbamol | 45 | $752 | $17 |
| Diclofenac | 34 | $676 | $20 |
| Gabapentin | 28 | $289 | $10 |
| Duloxetine | 21 | $274 | $13 |
| Ibuprofen | 22 | $183 | $8 |
| Meloxicam | 16 | $60 | $4 |
2022: 5 drugs
| Lidocaine | 20 | $1,982 | $99 |
| Pregabalin | 18 | $606 | $34 |
| Diclofenac | 19 | $314 | $17 |
| Methocarbamol | 15 | $180 | $12 |
| Ibuprofen | 11 | $84 | $8 |
2021: 3 drugs
| Lidocaine | 29 | $2,679 | $92 |
| Gabapentin | 23 | $463 | $20 |
| Meloxicam | 12 | $55 | $5 |
2020: 3 drugs
| Lidocaine | 23 | $1,421 | $62 |
| Gabapentin | 41 | $596 | $15 |
| Meloxicam | 11 | $28 | $3 |
2019: 1 drug
| Lidocaine | 12 | $729 | $61 |
2018: 2 drugs
| Gabapentin | 29 | $518 | $18 |
| Baclofen | 14 | $297 | $21 |
2017: 13 drugs
| Lyrica | 16 | $8,625 | $539 |
| Lidocaine | 49 | $3,467 | $71 |
| Gabapentin | 148 | $1,698 | $11 |
| Diclofenac | 24 | $1,651 | $69 |
| Baclofen | 38 | $809 | $21 |
| Hydrocodone-Acetaminophen | 44 | $762 | $17 |
| Tizanidine | 41 | $595 | $15 |
| Topiramate | 67 | $381 | $6 |
| Duloxetine | 11 | $378 | $34 |
| Acetaminophen-Codeine | 17 | $335 | $20 |
| Naproxen | 15 | $129 | $9 |
| Ibuprofen | 19 | $117 | $6 |
| Tramadol | 16 | $112 | $7 |
2016: 26 drugs
| Lidocaine | 241 | $43,862 | $182 |
| Hydrocodone-Acetaminophen | 447 | $12,917 | $29 |
| Oxycontin | 19 | $12,065 | $635 |
| Lyrica | 22 | $11,518 | $524 |
| Hysingla Er | 25 | $10,938 | $438 |
| Nucynta Er | 16 | $6,408 | $401 |
| Gabapentin | 325 | $4,699 | $14 |
| Oxycodone-Acetaminophen | 72 | $4,242 | $59 |
| Morphine Sulfate Er | 56 | $2,884 | $51 |
| Oxycodone | 72 | $2,695 | $37 |
| Fentanyl | 36 | $2,199 | $61 |
| Tizanidine | 108 | $1,790 | $17 |
| Morphine Sulfate | 45 | $1,272 | $28 |
| Voltaren | 23 | $1,134 | $49 |
| Diclofenac | 27 | $880 | $33 |
| Topiramate | 135 | $875 | $6 |
| Baclofen | 37 | $633 | $17 |
| Methocarbamol | 28 | $546 | $20 |
| Tramadol | 70 | $524 | $7 |
| Naproxen | 69 | $464 | $7 |
| Acetaminophen-Codeine | 25 | $447 | $18 |
| Methadone | 20 | $441 | $22 |
| Ibuprofen | 34 | $334 | $10 |
| Meloxicam | 82 | $313 | $4 |
| Amitriptyline | 14 | $211 | $15 |
| Venlafaxine Hcl Er | 11 | $90 | $8 |
2015: 14 drugs
| Oxycontin | 23 | $16,427 | $714 |
| Lidocaine | 26 | $4,950 | $190 |
| Hydrocodone-Acetaminophen | 71 | $2,735 | $39 |
| Oxycodone | 31 | $1,335 | $43 |
| Morphine Sulfate Er | 14 | $813 | $58 |
| Gabapentin | 50 | $770 | $15 |
| Voltaren | 11 | $695 | $63 |
| Hydromorphone | 13 | $442 | $34 |
| Methadone | 18 | $432 | $24 |
| Baclofen | 19 | $307 | $16 |
| Methocarbamol | 13 | $264 | $20 |
| Topiramate | 14 | $142 | $10 |
| Tramadol | 15 | $105 | $7 |
| Meloxicam | 25 | $73 | $3 |
2013: 1 drug
| Baclofen | 12 | $101 | $8 |
Money from drug and device companies
$299 in 2025
| 2025 | 9 | 13 | None | $299 |
| 2024 | 13 | 19 | None | $678 |
| 2023 | 6 | 19 | None | $634 |
| 2022 | 11 | 24 | None | $904 |
| 2021 | 7 | 12 | None | $238 |
| 2020 | 6 | 15 | None | $560 |
| 2019 | 4 | 15 | None | $598 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | General - Pain Management | $68 | 2 payments
|
| Stryker | N/A | $68 | 2 payments
|
| Solventum | V.A.C.Ulta | $49 | 2 payments
|
| Bioventus | Exogen Ultrasound Bone Healing System | $26 | 1 payment
|
| Globus Medical | Senza | $26 | 1 payment
|
| Djo | Donjoy | $17 | 1 payment
|
See all 13 published payments
| Abbott Laboratories | Meals · 2025-12-08 | Proclaim | $14 |
| Stryker | Meals · 2025-11-12 | Sonopet Iq | $14 |
| Boston Scientific | Meals · 2025-10-24 | General - Pain Management | $17 |
| LifeNet Health | Meals · 2025-09-17 | Theragenesis Wound Matrix | $12 |
| Solventum | Meals · 2025-09-15 | Activ.A.C. | $22 |
| LifeNet Health | Meals · 2025-08-12 | Theragenesis Wound Matrix | $2 |
| Heron Therapeutics | Meals · 2025-07-28 | Zynrelef | $16 |
| Boston Scientific | Meals · 2025-06-25 | General - Pain Management | $51 |
| Globus Medical | Meals · 2025-05-14 | Senza | $26 |
| Stryker | Meals · 2025-03-28 | N/A | $54 |
| Bioventus | Meals · 2025-03-20 | Exogen Ultrasound Bone Healing System | $26 |
| Solventum | Meals · 2025-02-05 | V.A.C.Ulta | $27 |
| Djo | Meals · 2025-01-26 | Donjoy | $17 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $678
| Abbott Laboratories | Eterna | $146 | 3 payments
|
| Nevro | Senza | $135 | 1 payment
|
| Biotronik Nro | Prospera | $91 | 3 payments
|
| Arteriocyte Medical Systems | Magellan | $63 | 1 payment
|
| SPR Therapeutics | Sprint Pns System | $47 | 1 payment
|
| Nalu Medical | Nalu Neurostimulation System | $44 | 1 payment
|
| Stryker | Adherus Autospray Dural Sealant | $31 | 1 payment
|
| Orthofix Medical | Spinal-Stim | $24 | 1 payment
|
| Medtronic | Intellis Adaptivestim | $24 | 1 payment
|
| Boston Scientific | Intracept | $23 | 1 payment
|
| Saluda Medical Americas | Evoke | $19 | 1 payment
|
| Solventum | V.A.C.Ulta | $16 | 1 payment
|
| Djo | Procare | $14 | 1 payment
|
2023: $634
| Abbott Laboratories | Proclaim | $202 | 5 payments
|
| Medtronic | Intellis Adaptivestim | $174 | 8 payments
|
| SPR Therapeutics | Sprint Pns System | $155 | 2 payments
|
| Smith+Nephew | Stravix | $41 | 1 payment
|
| Stratus Medical | Nimbus | $40 | 2 payments
|
| Saluda Medical Americas | Evoke Scs | $23 | 1 payment
|
2022: $904
| Boston Scientific | General - Pain Management | $364 | 7 payments
|
| Nevro | Omnia | $210 | 4 payments
|
| Abbott Laboratories | Octrode | $116 | 4 payments
|
| Medtronic | Vanta Adaptivestim | $44 | 1 payment
|
| Integra LifeSciences | Codman Certas | $36 | 2 payments
|
| Abbvie | Botox | $32 | 1 payment
|
| Bioventus | Durolane | $28 | 1 payment
|
| DePuy Synthes Sales | Orthovisc | $23 | 1 payment
|
| Microtransponder | None | $20 | 1 payment
|
| Avanos Medical | Generator | $16 | 1 payment
|
| Merit Medical Systems | Stabilit | $16 | 1 payment
|
2021: $238
| Boston Scientific | General Pain Management | $99 | 5 payments
|
| Nevro | Omnia | $32 | 1 payment
|
| Stimwave Technologies | Stimq Receiver Stimulator Kit Channel A US W Receiver | $26 | 2 payments
|
| Nalu Medical | Nalu Neurostimulation System | $23 | 1 payment
|
| Relievant Medsystems | Intracept | $20 | 1 payment
|
| Abbott Laboratories | Proclaim Ipg | $20 | 1 payment
|
| Spinal Elements | Medical Device | $18 | 1 payment
|
2020: $560
| Boston Scientific | Infinion | $255 | 10 payments
|
| Stimwave Technologies | Cfns Stimq Peripheral Nerve Stimulatorsystem | $189 | 1 payment
|
| Avanos Medical | Generator | $66 | 1 payment
|
| Nevro | Senza Spinal Cord Stimulation System | $19 | 1 payment
|
| Stryker | Yukon | $15 | 1 payment
|
| Medtronic USA | Intellis | $15 | 1 payment
|
2019: $598
| Abbott Laboratories | Proclaim Family of Scs Ipgs | $293 | 6 payments
|
| Boston Scientific | Infinion | $166 | 6 payments
|
| Nevro | Senza Spinal Cord Stimulation System | $122 | 2 payments
|
| Zyla Life Sciences | Sprix | $17 | 1 payment
|
Professional record
- NPI
- 1407171036
- Licence
- CA A121052California A121052: Current · expires 2027-10-31
- Trained
- University of California, Irvine, California College of Medicine, 2010 · 16 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2081P2900X (2081P2900X); Federal specialty code 208VP0014X (208VP0014X)
- Mailing address
- 2767 Olive Hwy, Oroville, CA, 95966
- NPI first listed
- 2010-04-07
- NPI last updated
- 2021-11-30
- NPI record certified
- 2021-11-30
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.